JOP20170172B1 - أملاح إضافة لحمض من مشتق بنزيميدازول - Google Patents

أملاح إضافة لحمض من مشتق بنزيميدازول

Info

Publication number
JOP20170172B1
JOP20170172B1 JOP/2017/0172A JOP20170172A JOP20170172B1 JO P20170172 B1 JOP20170172 B1 JO P20170172B1 JO P20170172 A JOP20170172 A JO P20170172A JO P20170172 B1 JOP20170172 B1 JO P20170172B1
Authority
JO
Jordan
Prior art keywords
acid addition
addition salts
benzimidazole derivative
stability
phase stability
Prior art date
Application number
JOP/2017/0172A
Other languages
English (en)
Inventor
Eun Sun Kim
Min Kyoung Lee
Sung Ah Lee
Kwang Do Choi
Jae Sun Kim
Hyung Chul Yoo
Original Assignee
Hk Inno N Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hk Inno N Corp filed Critical Hk Inno N Corp
Publication of JOP20170172A1 publication Critical patent/JOP20170172A1/ar
Application granted granted Critical
Publication of JOP20170172B1 publication Critical patent/JOP20170172B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

يتعلق الاختراع الحالي بملح بيدولات وملح مالات لمركب مُمثل بواسطة صيغة 1 مع استقرار ممتاز لطور سائل، واستقرار ممتاز لطور صلب، ذوبان ممتاز في الماء، استقرار ترسيب ممتاز واسترطاب ممتاز جميعها معًا كمركب للوقاية من وعلاج الأمراض التي تحدث بواسطة نشاط مناهض لضخ حمض، وكذلك طريقة لتحضيرهما.
JOP/2017/0172A 2016-09-21 2017-09-20 أملاح إضافة لحمض من مشتق بنزيميدازول JOP20170172B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020160120996A KR101829706B1 (ko) 2016-09-21 2016-09-21 벤즈이미다졸 유도체의 산부가염

Publications (2)

Publication Number Publication Date
JOP20170172A1 JOP20170172A1 (ar) 2019-01-30
JOP20170172B1 true JOP20170172B1 (ar) 2022-03-14

Family

ID=61387666

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2017/0172A JOP20170172B1 (ar) 2016-09-21 2017-09-20 أملاح إضافة لحمض من مشتق بنزيميدازول

Country Status (13)

Country Link
US (3) US11535610B2 (ar)
EP (1) EP3517528B1 (ar)
JP (1) JP6814891B2 (ar)
KR (1) KR101829706B1 (ar)
CN (1) CN109769392B (ar)
AR (1) AR109679A1 (ar)
ES (1) ES2896802T3 (ar)
JO (1) JOP20170172B1 (ar)
MX (1) MX2019003171A (ar)
MY (1) MY197242A (ar)
PH (1) PH12019500602A1 (ar)
TW (1) TWI659028B (ar)
WO (1) WO2018056697A1 (ar)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200024413A (ko) * 2018-08-28 2020-03-09 에이치케이이노엔 주식회사 항혈소판제와 산 분비 억제제를 포함하는 약학 조성물
JOP20190201A1 (ar) * 2018-08-29 2020-02-29 Hk Inno N Corp تركيبة لاستئصال الملوية البوابية
JOP20210226A1 (ar) * 2019-02-18 2023-01-30 Hk Inno N Corp تركيبة صيدلانية تشتمل على مركب مشتق بنزيميدازول
BR112022025169A2 (pt) * 2020-06-12 2022-12-27 Hk Inno N Corp Uso de uma composição farmacêutica compreendendo composto derivado de benzimidazol, um sal farmaceuticamente aceitável do mesmo, um hidrato ou solvato do mesmo, ou uma mistura dos mesmos
MX2023004611A (es) * 2020-10-23 2023-05-08 Hk Inno N Corp Comprimido de desintegracion oral que comprende un compuesto derivado de benzimidazol y procedimiento de preparacion del mismo.
TWI822151B (zh) * 2021-07-02 2023-11-11 南韓商Ｌｇ化學股份有限公司 製備黃嘌呤氧化酶抑制劑的方法
KR102648315B1 (ko) * 2021-12-08 2024-03-15 (주) 팜젠사이언스 벤즈이미다졸 유도체 화합물 및 이의 용도
KR20230114163A (ko) 2022-01-24 2023-08-01 엠에프씨 주식회사 칼륨 경쟁적 위산분비억제제 계열 약물의 신규한 무정형 고체분산체 및 그의 제조방법
KR20240120271A (ko) 2023-01-31 2024-08-07 주식회사 엔비피헬스케어 신규한 테고프라잔 말론산 공무정형
WO2024171128A1 (en) * 2023-02-18 2024-08-22 Lee Pharma Limited Stable amorphous form of potassium-competitive acid blocker and process for the preparation thereof
KR20240131641A (ko) 2023-02-24 2024-09-02 엠에프씨 주식회사 신규 테고프라잔의 염 결정형 및 이의 용매화물 결정형, 및 이들의 제조방법
WO2024185939A1 (ko) * 2023-03-09 2024-09-12 이니스트에스티 주식회사 크로메인 치환된 벤즈이미다졸 유도체 및 코포머로써 무기염을 포함하는 공동무정형 고체
KR102715562B1 (ko) 2023-03-16 2024-10-11 (주) 에프엔지리서치 테고프라잔의 신규 염 및 이의 제조 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042485A1 (en) * 2003-10-30 2005-05-12 Sk Chemicals, Co., Ltd. Acid added salts of amlodipine
EP1695973A1 (en) * 2005-02-24 2006-08-30 Neuro3D Ocaperidone salt and pharmaceutical compositions containing the same
DE602006009105D1 (de) 2005-06-14 2009-10-22 Raqualia Pharma Inc Chroman-substituierte benzimidazolderivate als säurepumpenantagonisten
CA2631880C (en) 2005-12-19 2011-03-29 Pfizer Inc. Chromane substituted benzimidazoles and their use as acid pump inhibitors
EP2650299A1 (en) * 2008-07-03 2013-10-16 Ratiopharm GmbH Crystalline salts of sitagliptin
KR102187034B1 (ko) * 2009-01-16 2020-12-04 엑셀리시스, 인코포레이티드 암 치료용 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
EP2452680B1 (en) * 2009-07-09 2019-12-18 RaQualia Pharma Inc. Acid pump antagonist for the treatment of diseases involved in abnormal gastrointestinal motility
KR101684053B1 (ko) * 2015-01-20 2016-12-08 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법
KR102262743B1 (ko) 2017-07-07 2021-06-09 에이치케이이노엔 주식회사 주사용 조성물

Also Published As

Publication number Publication date
CN109769392B (zh) 2022-06-24
JP6814891B2 (ja) 2021-01-20
MX2019003171A (es) 2019-06-10
JOP20170172A1 (ar) 2019-01-30
US20240150331A1 (en) 2024-05-09
EP3517528A4 (en) 2020-05-20
US20230192670A1 (en) 2023-06-22
US11535610B2 (en) 2022-12-27
US20210292307A1 (en) 2021-09-23
TWI659028B (zh) 2019-05-11
ES2896802T3 (es) 2022-02-25
US11912690B2 (en) 2024-02-27
CN109769392A (zh) 2019-05-17
JP2019529557A (ja) 2019-10-17
EP3517528B1 (en) 2021-09-01
EP3517528A1 (en) 2019-07-31
MY197242A (en) 2023-06-07
KR101829706B1 (ko) 2018-02-19
TW201815786A (zh) 2018-05-01
WO2018056697A1 (ko) 2018-03-29
BR112019005505A2 (pt) 2019-06-04
PH12019500602A1 (en) 2019-11-11
AR109679A1 (es) 2019-01-09

Similar Documents

Publication Publication Date Title
JOP20170172B1 (ar) أملاح إضافة لحمض من مشتق بنزيميدازول
MX2017014613A (es) Compuestos de bencimidazol e imadazopiridin-carboximidamida que tienen actividad como inhibidores de indolamina 2,3-dioxigenasa.
MX2023001876A (es) Derivados de rapamicina.
PH12019500480A1 (en) Pyridine compound
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12018500360A1 (en) Heteroaryl derivatives as parp inhibitors
PH12020551014A1 (en) Amino-fluoropiperidine derivatives as kinase inhibitor
PH12017500111A1 (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
EA202091505A1 (ru) Триазолазолы циклогексильной кислоты в качестве антагонистов lpa
WO2016077464A8 (en) Amino acid derivatives and their uses
NZ764644A (en) Oxy-fluoropiperidine derivative as kinase inhibitor
ZA201707152B (en) Methods for hydraulic enhancement of crops
MX2018014164A (es) Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico.
CO2020007222A2 (es) Proceso para la preparación de derivados antihelmínticos de 4-amino-quinolin-3-carboxamida
MX2017000208A (es) Derivados de quinolizinona como inhibidores de pi3k.
MX2016013265A (es) Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp.
MX2018004055A (es) Compuestos de imino con un sustituyente de 2-cloropirimidin-5-ilo como agentes de control de plagas.
PH12017501404A1 (en) Diaza-benzofluoranthrene compounds
EA201692140A1 (ru) Производные аминопиридина в качестве ингибиторов фосфатидилинозитол 3-киназы
MX2016010564A (es) Procesos para preparar moduladores del canal ionico heterociclico fusionado.
UA118283C2 (uk) Гербіцидні сполуки
EA202090438A1 (ru) Производные глицерретиновой кислоты для лечения гиперкалиемии
PH12018501046A1 (en) Crystals of monovalent cation salt of 3-hydroxyisovaleric acid, and method for producing said crystals
CO2020006788A2 (es) Método de producción de un compuesto intermedio para sintetizar un medicamento
UA112888U (xx) Спосіб паралельного синтезу аліфатичних оксамідів